Clarity Pharmaceuticals Ltd.ASX: CU6

Quarterly Activities/Appendix 4C Cash Flow Report

· Issued by Clarity Pharmaceuticals Ltd. via ASX

Filed with ASX ·

SYDNEY, AUSTRALIA 30 JUNE 2026 QUARTERLY ACTIVIT Y REPORT Cash Position The Company remains well funded with a cash position of $178.3 million at 30 June 2026, providing Clarity with a strong Balance Sheet to continue progressing its products towards commercialisation. The Company...

View Attachment

6ix hasn’t read this filing yet.

Clarity Pharmaceuticals Ltd. on 6ix

Earlier from Clarity Pharmaceuticals

Later from Clarity Pharmaceuticals

All Clarity Pharmaceuticals news releases